Whittier Trust Co. of Nevada Inc. Has $8.62 Million Stock Position in IQVIA Holdings Inc. $IQV

Whittier Trust Co. of Nevada Inc. grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 2.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 54,680 shares of the medical research company’s stock after buying an additional 1,076 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in IQVIA were worth $8,617,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after buying an additional 131 shares during the period. Golden State Wealth Management LLC grew its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after buying an additional 130 shares during the period. AllSquare Wealth Management LLC acquired a new position in shares of IQVIA in the 1st quarter valued at $33,000. Trust Co. of Toledo NA OH acquired a new position in shares of IQVIA in the 2nd quarter valued at $39,000. Finally, J.Safra Asset Management Corp grew its holdings in shares of IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after buying an additional 169 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 3.8%

Shares of NYSE:IQV opened at $212.30 on Tuesday. The company’s 50-day moving average price is $192.05 and its two-hundred day moving average price is $169.60. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $235.32. The stock has a market capitalization of $36.09 billion, a PE ratio of 30.72, a price-to-earnings-growth ratio of 2.25 and a beta of 1.32.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. During the same period in the previous year, the firm posted $2.64 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on IQV. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Evercore ISI upped their target price on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $195.00 to $225.00 in a research note on Tuesday, September 9th. Finally, Robert W. Baird upped their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $234.57.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company’s stock, valued at $557,352.30. The trade was a 15.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.